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Abstract: The aim of the present study was to characterize Enterobacterales resistant to 3rd and
4th generation cephalosporins, carbapenems and/or fluoroquinolones, isolated from dogs and
cats with urogenital infections. In total, 36 strains (Escherichia coli (n = 28), Klebsiella pneumoniae
(n = 3), Serratia marcescens, Raoultella ornithinolytica, Proteus mirabilis, Citrobacter portucalensis and
Enterobacter cloacae (each n = 1)) were included in the present study, 28 from Austria and 8 from
Serbia. Isolates were characterized by a polyphasic approach including susceptibility pheno- and
genotyping and microarray-based assays. Escherichia (E.) coli isolates were additionally characterized by
two-locus (fumC and fimH) sequence phylotyping and multi-locus sequence typing (MLST) of selected
isolates. MLST of carbapenem-resistant Enterobacter cloacae isolates was also performed. Among E. coli,
the most dominant phylogenetic group was B1 (27.8%), followed by C, (16.6%), A and Clade II (5.5%
each), B2 and F (2.77% each). The most predominant β-lactam resistance genes were blaTEM (70%) and
blaCTX-M (38.8%), blaCMY (25%). blaNDM was detected in one carbapenem-resistant Enterobacter cloacae
ST114. The most common ST among selected E. coli was 744 (10.7% isolates). The pandemic clones ST131
and ST648 carrying CTX-M-15 were also detected. Remaining STs belonged to 469, 1287, 1463 and 1642.
E. coli clonotyping revealed 20 CH types. Based on the presence of certain virulence genes, three isolates
were categorized as ExPEC/UPEC. The most prevalent virulence factors were fimH detected in 61%, iucD
and iss both in 55%, iroN in 27.8%, papC in 13.8% and sat in 8.3% isolates.
Keywords: urogenital system; infection; cephalosporins; fluoroquinolones; Enterobacterales; ESBL;
AmpC; carbapenem-resistant; pandemic clone; ST131; ST648; ST114
1. Introduction
The most common causative agents of urogenital infections (UGI) are the members of the order
Enterobacterales, amongst them primarily Escherichia (E.) coli with a prevalence in companion animals
between 35–70% [1] and in humans between 75–95% [2]. UGI include infections of the bladder, kidneys
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and urethra and in adult animals also parts of the genital tract such as the uterus in females and prostate
in males [3]. E. coli capable of causing UGI is termed uropathogenic E. coli (UPEC) [1,4]. UPECs belong
to extraintestinal pathogenic E. coli (ExPEC), which are phylogenetically and epidemiologically distinct
from commensal E. coli due to a characteristic combination of virulence factors [1,5–7]. The ExPEC
category should simplify the highly complicated categorization of non-intestinal pathogenic E. coli
and encompass numerous subcategories which besides UPECs include sepsis-associated E. coli
(SEPEC), neonatal meningitis-associated E. coli (NEMEC) and avian-pathogenic E. coli (APEC) [1,8].
UGIs can also be caused by DAECs (diffusely adhering E. coli) which in parallel belong to both the
extraintestinal and intestinal pathogenic E. coli categories [9]. Opportunistic intestinal E. coli and
other intestinal Enterobacterales, which typically lack specific virulence determinants may also cause
UGIs [10]. Transmission of UPECs via meat to the human urinary tract has been described and
therefore, “foodborne uropathogens” that cause “foodborne urinary tract infections” or FUTI have also
been introduced [1,2,11]. It has been shown that the above-mentioned ExPEC subcategories mostly
share the same virulence factors. They may originate from the human intestinal tract, the environment,
livestock, meat products, sewage and companion animals and can cross host species barriers and cause
different types of zoonotic infections including UGIs [1,8,10–13]. Typical representatives are E. coli
B2-O25b:H4-ST131 and E. coli F-ST648 [2,5,6,10–12,14–16]. Also, the categorization presented here is
mostly related to the pathotypes and the origin of isolation, a specific molecular marker for the precise
determination of every subcategory is still not defined [17].
Antibiotics are in addition to the uptake of sufficient water essential for the treatment of
UGIs [2]. Unfortunately, therapy of UGIs is known to be initiated by the empirical selection of
antibiotic agents before microbiological examinations are completed [6,18–20]. For the selection
of antibiotics, recommendations made by competent institutions and bodies should be followed.
For the treatment of noncomplicated UGI, the International Society for Companion Animal Infectious
Disease Committee (ISCAID) recommends amoxicillin or trimethoprim–sulfonamide as first-choice
antibiotics, emphasizing that amoxicillin-clavulanic acid should only be the second choice or avoided if
possible [18]. All recommendations discourage veterinarians from using fluoroquinolones or 3rd and
4th generation cephalosporins as first-line antibiotics except if there is a clear indication. The increasing
resistance to fluoroquinolones and β-lactam antibiotics in Enterobacterales with the dominance of
CMY- and CTX-M-group harboring strains [2,20–24] but also to so-called “traditional” antibiotics
such as sulfamethoxazole-trimethoprim and tetracyclines, somehow renders the recommendations
given, limits therapeutic choices and urges clinicians to seek for broader spectrum agents for the
treatment of UGIs. In the European Union, including Austria, especially at the University of Veterinary
Medicine, Vienna, veterinarians are advised to follow strict guidelines for the use of antibiotics.
Except for few countries including the Netherlands and France, veterinarians are allowed to use
human-related antibiotics in companion animals, even carbapenems, but only in strictly defined and
justified cases [25–28]. Despite carbapenems have no legal indication in some countries and are not
used in routine practice, ISCAID and other relevant institutions have included carbapenems in their
official documentation related to animals [18,29]. Close contact between humans and companion
animals contributes to the propagation and exchange of resistance genes between bacteria as well as
the direct transmission of all ExPEC subcategories including UPECs, so human-related clones have
already been detected in companion animals [27,30–32]. As a consequence, companion animals are
more and more considered an important source of human infections both by ExPEC/UPEC and by
multidrug-resistant bacteria (MDR) in general [20,26,33–36].
In the present study, we have characterized a collection of canine and feline Enterobacterales
associated with UGI, which were resistant to critically important antibiotics for humans (i.e., 3rd and
4th generations cephalosporins, carbapenems and/or fluoroquinolones) by a multiphasic approach.
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2. Results
In Austria, isolates belonging to the order Enterobacterales were detected in 550 of 2398 samples
resulting in a carriage rate of 22.94% whereas 28 isolates were broad-spectrum cephalosporin-resistant
and/or fluoroquinolone-resistant resulting in a carriage rate of 1.17% over all tested animals.
We observed higher carriage rates in Serbia. In 45 out of 144 samples (carriage rate 31.25%), isolates
belonging to Enterobacterales were detected whereas eight were broad-spectrum cephalosporin-resistant
and/or fluoroquinolone-resistant resulting in a carriage rate of 5.56% over all tested animals.
Twenty-eight isolates were identified as E. coli and the remaining isolates were Klebsiella pneumoniae
(n = 3), Raoultella ornithinolytica (n = 1), Citrobacter portucalensis (n = 1), Proteus mirabilis (n = 1),
Serratia marcescens (n = 1) and Enterobacter cloacae (n = 1) (Tables 1 and 2). All isolates were resistant to at
least one antibiotic from at least three different classes and accordingly, were categorized as MDR [37].
They originated from dogs (n = 30) and cats (n = 6), wherefrom 58.3% (n = 21) were isolated from urine
(obtained via cystocentesis, which is routine), 27.8% (n = 10) from the vagina, 2,7% (n = 1) from an
ejaculate, 5.5% (n = 2) from the prostate gland and 5.5% (n = 2) from the bladder wall.
All isolates examined were susceptible to amikacin and only one (Enterobacter cloacae) was resistant
to meropenem. Low resistance to nitrofurantoin and fosfomycin (in one Klebsiella pneumoniae and
Enterobacter cloacae isolate) was observed. In fourteen isolates (E. coli (n = 11), Klebsiella pneumoniae (n = 1),
Citrobacter portucalensis (n = 1) and Enterobacter cloacae (n = 1)), genes from the blaCTX-M family were
detected, alone or in combination with other bla genes. In nine E. coli isolates exhibiting the AmpC/ESBL
phenotype, blaCMY alone or together with mutation events in the ampC promoter/attenuator region
were found. In two isolates displaying the AmpC phenotype, these mutations were detected without
the presence of blaCMY or other bla genes (Tables 1 and 2). New Delhi metallo-β-lactamase (blaNDM-1)
was found in one carbapenem-resistant Enterobacter cloacae from Serbia. The same isolate harbored
blaCTX-M-15, blaNDM and blaOXA-1. Ciprofloxacin resistance was found in 86.1% (n = 31) isolates.
Plasmid mediated quinolone resistance (PMQR) genes were identified in 33.3% (n = 12) isolates,
of which nine isolates harbored qnrB and 3 isolates qnrS genes. In all but three ciprofloxacin-resistant
isolates, amino acid substitutions were detected in the QRDR of gyrA and/or parC. The genes sul1,
sul2 and tet(A) were the most prevalent non-β-lactamase genes and non-PMQR detected.
The most dominant phylogenetic group was B1 (n = 10), followed by C (n = 6), B2 (n = 3), A and
Clade II (n = 2) and singleton F. In two isolates the phylogroup could not be determined (Table 1).
E. coli clonotyping revealed 18 fumC and fimH (CH) types obtained after DNA sequencing of these
housekeeping genes. The most prevalent were CH11-0 and CH11-54 (n = 4), wherefrom five selected
isolates belonged to three different STs (ST744, ST1287 and ST1642). Other prevalent CH types were
CH65-32 (n = 3); thereof one selected isolate belonged to ST469, CH40-30 (n = 2), represented by ST131
and CH4-27 (n = 2) with one isolate belonging to ST648. The remaining clonotypes were singletons
CH4-61, CH4-31, CH6-35, CH10-58, CH11-23, CH40-22, CH41-86, CH65-58, CH95-31, CH95-60,
CH99-54, CH1430-142 and CH675-61 (Table 1, Figure 1). E. coli serogenotypes (somatic O and flagellar
H antigens) were clearly determined in 8 isolates. MLST of blaNDM-1 positive Enterobacter cloacae
revealed that this isolate belonged to ST114 (Table 2).
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Table 1. Molecular characterization and resistance to antibiotics of canine and feline E. coli isolated from urogenital infections and originating from Austria (AUT) and
Serbia (SRB).
Serogenotyping Clonotype ST * Resistance Profile Mutation
Isolate Country Host Source Species Phylogroup O H fumC fimH Phenotype ** Genotype ampCpromoter gyrA parC
Previous
therapy **
MDR56 SRB dog vaginalswab E. coli A 128 26 11 23 n.t.
AMP, CIP,
CHL, SXT
blaTEM, catA1,
tet(B), dfrA17
Ser83Leu,
Asp87Asn Ser80Ile AMC, ENO
MDR63 SRB dog urine E. coli C 9 9 11 0 n.t.
AMP, CAZ,
CTX, CIP, TET,
CHL, SXT
blaTEM, blaCMY,
strA, strB, tet(B),
catA1, sul1, sul2,
dfrA17, dfrA19
w.t. Ser83Leu,Asp87Asn Ser80Ile not known
193 AUT dog bladder E. coli B1 n.d. 16 65 32 n.t.
AMP, CAZ,
CTX, CIP, TOB,
TET, SXT
blaTEM, blaCMY,
qnrB, aac(6),
aac(6)-Ib, strB,
tet(A), sul1, sul2,
dfrA5
–18, –1, +58 Ser83Leu,Asp87Asn Ser80Ile not known
2304 AUT dog urine E. coli B1 n.d. 23 675 61 n.t. AMP, CAZ,CTX, CIP blaTEM, blaCMY –18, –1, +58
Ser83Leu,
Asp87Asn Ser80Ile CIP
3056 AUT dog urine E. coli unknown 25 4 40 30 n.t.
AMP, CAZ,
CTX, ATM, CIP,
GEN, TOB, TET
blaCTX-M-1,
blaOXA-1,
aac(6)-Ib, tet(A),
catB3
Ser83Leu,
Asp87Asn
Ser80Ile,
Glu84Val
AMC,
Cephalosporin
3168 AUT dog urine E. coli B1 n.d. 16 65 32 n.t.
AMP, CAZ,
CTX, CIP, TOB,
TET, SXT
blaTEM, blaCMY,
qnrB, aac6Ib,
tet(A), sul1, sul2,
dfrA5
–18, –1, +58 Ser83Leu,Asp87Asn Ser80Ile
AMC, MAR,
CVN
2016 AUT dog urine E. coli B1 n.d. 8 41 86 n.t. AMP, CTX, FEP,ATM, TET
blaCTX-M-1,
blaTEM, qnrS,
aphA, strA, strB,
tet(A), sul2
ENO, CVN
2058 AUT dog urine E. coli unknown 25 4 40 22 n.t. AMP, CTX,ATM, TET, CHL
blaCTX-M-1,
blaTEM, strA,
strB, tet(A), floR
none
4125 AUT dog urine E. coli B1 n.d. 16 65 58 n.t.
AMP, CAZ,
CTX, CIP, TOB,
TET, SXT
blaTEM, blaCMY,
qnrB, aac(6),
aac(6)-Ib, strA,
strB, tet(A), sul1,
sul2, dfrA5
–18, –1, +58 Ser83Leu,Asp87Asn Ser80Ile CHL
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Table 1. Cont.
Serogenotyping Clonotype ST * Resistance Profile Mutation
Isolate Country Host Source Species Phylogroup O H fumC fimH Phenotype ** Genotype ampCpromoter gyrA parC
Previous
therapy **
1286 AUT cat urine E. coli clade II n.d. n.d. 4 27 n.t.
AMP, CAZ,
CTX, ATM, CIP,
TOB, TET, SXT
blaCMY,
blaOXA-1, blaTEM,
aac(6), aac(6)-Ib,
aadA4, strB,
catB3, tet(A),
sul2, dfrA17
+58 Ser83Leu,Asp87Asn Ser80Ile none
2269 AUT dog ejaculate E. coli C n.d. 30 99 54 n.t. AMP, CIP,GEN, TOB
blaOXA-1, aac(6),
aac(6)-Ib, catB3
Ser83Leu,
Asp87Asn w.t. none
2736 AUT dog urin E. coli B1 n.d. 23 4 61 n.t. AMP, CIP, TET tet(A) Ser83Leu,Asp87Asn Ser80Ile ENO
3441 AUT dog urin E. coli C n.d. 9 4 31 744
AMP, CAZ,
CTX, CIP, TET,
CHL, SXT
blaCTX-M-1,
blaTEM, aadA1,
aadA4, aphA,
strB, tet(A),
tet(B), catA1,
sul1, sul2, dfrA1,
dfrA17
Ser83Leu Ser80Ile CHL
3448 AUT cat urin E. coli C n.d. 9 11 0 744
AMP, CAZ,
CTX, ATM, CIP,
TET, CHL, SXT
blaCTX-M-1,
blaTEM, aadA2,
aadA4, aphA,
strA, strB, tet(A),
tet(B), catA1,
sul1, sul2, dfrA1,
dfrA17
Ser83Leu,
Asp87Asn Ser80Ile CHL
3534 AUT dog urin E. coli B1 n.d. 9 11 54 744
AMP, CAZ,
CTX, CIP, GEN,
TOB, TET,
CHL, SXT
blaTEM, aadA1,
aphA, strA, strB,
tet(B), catA1,
floR, sul2, dfrA1
Ser83Leu Ser80Ile none
482 AUT dog vagina E. coli C n.d. 9 1430 142 n.t. AMP, CAZ,CTX, ATM, CIP
blaCTX-M-1,
blaOXA-1, blaTEM,
aac(6), aac(6)-Ib,
aadA4, sul2,
dfrA17
Ser83Leu,
Asp87Asn Ser80Ile not known
4 AUT dog urine E. coli clade II n.d. 6 10 58 n.t.
AMP, CTX,
ATM, CIP, GEN,
TOB, TET, CHL
blaCTX-M-9,
blaTEM, strB,
tet(B), sul2,
dfrA17
+58 Ser83Leu,Asp87Asn
Ser80Ile,
Glu84Gly CVN
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Table 1. Cont.
Serogenotyping Clonotype ST * Resistance Profile Mutation
Isolate Country Host Source Species Phylogroup O H fumC fimH Phenotype ** Genotype ampCpromoter gyrA parC
Previous
therapy **
855 AUT dog vaginalswab E. coli C 9 9 11 54 1287
AMP, CTX, CIP,
TET, CHL, SXT
blaTEM, blaCMY,
aadA1, strB,
tet(B), catA1,
sul2, dfrA17
w.t. Ser83Leu,Asp87Asn Ser80Ile none
555 AUT dog prostatacyst E. coli B2 25b 4 40 30 131
AMP, CAZ,
CTX, FEP, CIP,
GEN, TOB,
TET, SXT
blaCTX-M-15,
blaOXA-1, aac(6),
aac(6)-Ib, aadA1,
aadA2, aadA4,
aadA5, tet(A),
catB3, sul1, sul2,
dfrA17
Ser83Leu,
Asp87Asn
Ser80Ile,
Glu84Gly none
260 AUT dog vaginalswab E. coli F n.d. 6 4 27 648
AMP, CAZ,
CTX, FEP, CIP,
GEN, TOB, TET,
CHL, SXT
blaCTX-M-15,
blaOXA-1,
aac(6)-Ib, aadA1,
aadA2, tet(A),
catB3, sul1, sul2
Ser83Leu,
Asp87Asn Ser80Ile not known
655 AUT dog urine E. coli B1 n.d. 7 4 31 n.t.
AMP, CAZ,
CTX, ATM, CIP,
TOB, TET, SXT
blaTEM, blaCMY,
aphA, strB, tet(B),
sul2
w.t. Ser83Leu,Asp87Asn Ser80Ile LEX
728 AUT dog vaginalswab E. coli B1 n.d. ND 65 32 469
AMP, CIP, TET,
CHL, SXT
qnrS, tet(B), sul2,
sul3, dfr12, straA
Ser83Leu,
Asp87Asn Ser80Ile none
2189 AUT cat urin E. coli B1 79 7 95 31 1463 AMP, CIP, TET,CHL
blaTEM, tet(B),
catA1 w.t. Ser80Ile not known
3512 AUT dog vaginalswab E. coli B1 n.d. 7 11 54 1642
AMP, CIP, GEN,
TOB, CHL
blaTEM, aadA4,
aphA, strB, tet(B),
sul1, sul2, dfrA17
Ser83Leu,
Asp87Asn w.t. none
2srb SRB dog urin E. coli B1 n.d. 10 6 35 n.t. AMP, CIP,TET, SXT
blaTEM, aadA1,
strA, tet(A), sul1,
sul2, dfrA7,
dfrA17
-18, –1, +58 Ser83Leu,Asp87Asn Ser80Ile not known
1srb SRB dog urin E. coli C n.d. 16 11 0 n.t. AMP, CIP, GEN,TET, SXT
blaTEM, blaOXA-2.
aadA4, strA, strB,
tet(A), sul1, sul2,
dfrA17
Ser83Leu,
Asp87Asn Ser80Ile not known
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Table 1. Cont.
Serogenotyping Clonotype ST * Resistance Profile Mutation
Isolate Country Host Source Species Phylogroup O H fumC fimH Phenotype ** Genotype ampCpromoter gyrA parC
Previous
therapy **
ESBL1 SRB cat vaginalswab E. coli C n.d. n.d. 11 0 n.t.
AMP, CAZ,
CTX, ATM, CIP,
TOB, TET, SXT
blaCTX-M-1,
blaOXA-1, blaTEM,
aac(6), aac(6)-Ib,
aadA4, strA, strB,
tet(A), sul1, sul2,
dfrA17
Ser83Leu,
Asp87Asn Ser80Ile AMC
ESBL41 SRB dog vaginalswab E. coli A n.d. n.d. 95 60 n.t.
AMP, CAZ,
CTX, CIP, GEN,
TOB, TET,
CHL, SXT
blaCTX-M-1,
blaTEM, aadA1,
aadA2, aphA,
strA, strB, tet(A),
sul1, sul2, dfrA14
Ser83Leu,
Asp87Asn Ser80Ile AMC
* sequence type. ** AMP-ampicillin, AMC-amoxicillin/clavulanate, LEX-cefalexin, CTX-cefotaxime, CAZ-ceftazidime, CVN-cefovecin, MEM-meropenem, ATM-aztreonam, FEP-cefepime,
CIP-ciprofloxacin, ENO-enrofloxacin, MAR-marbofloxacin, GEN-gentamicin, TOB-tobramycin, TET-tetracycline, CHL-chloramphenicol, SXT- trimethoprim/sulfamethoxazole,
NIT-nitrofurantoin, FOF-fosfomycin.
Table 2. Molecular characterization and resistance to antibiotics of canine and feline non-E. coli Enterobacterales isolated from urogenital infections and originating from
Austria (AUT) and Serbia (SRB).
Resistance Profile Mutation
Isolate Country Host Source Species ST * Phenotype ** Genotype gyrA parC Previoustherapy **
3srb SRB dog vaginalswab Serratia marcescens n.t.
AMP, CTX, TET,
CHL, SXT
blaTEM, aadA4,
aphA, strB, tet(B),
catA1
not known
1919 AUT dog urine Klebsiellapneumoniae n.t.
AMP, CTX, CIP,
GEN, TOB, TET
blaCTX-M-1,
blaOXA-1, qnrB,
aac(6), aac(6)-Ib,
catB3
Ser83Ile
codon 79Asp
silent
mutation
(GAT>GAC)
not known
3938 AUT dog urin Klebsiellapneumoniae n.t.
AMP, CAZ, CTX,
CIP, GEN, TOB,
TET, CHL, SXT
blaOXA-1, blaSHV,
aac(6), aac(6)-Ib,
qrnB, qnrS, aphA,
catB3, sul1
w.t. Ser80Ile not known
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Table 2. Cont.
Resistance Profile Mutation
Isolate Country Host Source Species ST * Phenotype ** Genotype gyrA parC Previoustherapy **
3824 AUT dog prostataswab
Klebsiella
pneumoniae n.t.
AMP, CAZ, CTX,
FEP, CIP, TOB,
SXT, NIT
blaOXA-1, blaSHV,
aac(6), aac(6)-Ib,
aphA, qrnB, catB3,
sul1, dfrA12
Asp87Asn Ser80Ile,Glu84Gly AMC, MAR
1049 AUT cat urin Raoultellaornithinolytica n.t.
AMP, CAZ, CTX,
CIP, GEN, TOB,
TET, CHL, SXT
blaTEM, aadA1,
aphA, tet(B), sul1,
catA1, sul2
w.t. w.t. not known
210 AUT dog urine Proteus mirabilis n.t. AMP, CTX, FEP,CHL, SXT
blaTEM, aadA1,
aphA, strA, strB,
catA1, sul2, dfrA1
none
3362 AUT cat bladder wall Citrobacterportucalensis n.t.
AMP, CAZ, CTX,
ATM, FEP,
CIP, SXT
blaCTX-M-1, blaCMY,
qrnB, strA, strB,
sul2, dfrA1
Ser83Leu w.t. MAR
ESBL40 SRB Dog vaginalswab Enterobacter cloacae 114
AMP, CAZ, CTX,
MEM, ATM, FEP,
CIP, TOB, TET,
CHL, SXT, FOF
blaNDM-1,
blaCTX-M-15,
blaOXA-1, blaTEM,
qnrB, aadA1, aac(6),
aac(6)-Ib, aadA2,
aphA, strA, strB,
tet(A), sul2, dfrA12,
dfrA14
Ser83Leu w.t. AMC, ENO
* sequence type. ** AMP-ampicillin, AMC-amoxicillin/clavulanate, LEX-cefalexin, CTX-cefotaxime, CAZ-ceftazidime, CVN-cefovecin, MEM-meropenem, ATM-aztreonam, FEP-cefepime,
CIP-ciprofloxacin, ENO-enrofloxacin, MAR-marbofloxacin, GEN-gentamicin, TOB-tobramycin, TET-tetracycline, CHL-chloramphenicol, SXT- trimethoprim/sulfamethoxazole,
NIT-nitrofurantoin, FOF-fosfomycin.
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Figure 1. goeBURST diagram for the CH clonotyping data set (CHs in parenthesis) of 28 E. coli isolates.
An eBURST diagram was calculated using PHYLOViZ with the goeBURST algorithm. E. coli isolates
were grouped according to their CH profiles.
In twenty-five isolates at least two VFs associated with ExPEC/UPEC were found. The largest number
withi a total of seven VFs associated with ExPEC/UPEC was detected in two CH40–30 clonotypes that
belonged to the B2 phylo roup, carried b aCTX-M-15 and harbored papC, fimH, iucD iha, nfa, sat, iss and
papC, fimH, iucD, sat, cnf1, iss, iha, re pe tively. Both i olates carried the H4 gene and allele-sp cific PCR
confirmed the presence of the rfbO25b locus of ST131 but also in an CF40-22 isolate (Table 3).
Table 3. Virulence factors detected in E. coli isolates obtained from dogs and cats with urogenital
infections and originating from Austria (AUT) and Serbia (SRB).
Isolate Country Host Source Species Virulence Factors
MDR56 SRB dog i al s ab E. coli tsh, mchF hemL, intl1, iroN, iss, fimH, iucD
MDR63 SRB dog ri E. coli senB, hemL, intl1, iss, iucD
193 AUT dog bladder E. coli mchF, hemL, intl1, iroN, iss
2304 AUT dog urine E. coli lpfA, mchF, hemL, iroN, iss, fimH
3056 AUT dog urine E. coli iha, prfB, cnf1, sat, iss. fimH, iucD, papC
3168 AUT dog urine E. coli hemL, iss, fimH, iucD
2016 AUT dog urine E. coli lpfA, cma, hemL, iroN, iss, fimH
2058 AUT dog urine E. coli prfB, mchF, iroN, iss, fimH, iucD, papC
4125 AUT dog urine E. coli lpfA, mchF, hemL, intl1, iroN, iss, fimH, iucD
1286 AUT cat urine E. coli prfB, hemL, iss, fimH, papC
2269 AUT dog ejaculate E. coli hemL, fimH, iucD
2736 AUT dog urin E. coli lpfA, hemL, fimH
3441 AUT dog urin E. coli tsh, cba, cma, mchF, hemL, intl1, iron, iss, fimH, iucD
3448 AUT cat ri E. coli tsh, cba, ma, mchF, hemL, intl1, iron, iss, fimH, iucD
3534 AUT dog ri E. coli prfB, mcmA, hemL, intl2 reA, fimH, iucD
482 AUT dog vagina E. coli hemL, fimH
4 AUT dog urine E. coli hemL, iss, fimH
855 AUT dog vaginal swab E. coli hemL, intl1, iroN, iss, iucD
555 AUT dog prostata cyst E. coli iha, nfaE, prfB, sat, senB, intl1, iss, fimh, iucD, papC
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Table 3. Cont.
Isolate Country Host Source Species Virulence Factors
260 AUT dog vaginal swab E. coli hemL, iss, fimH, iucD
655 AUT dog urine E. coli lpfA, hemL, iss, fimH, iucD
728 AUT dog vaginal swab E. coli
2189 AUT cat urin E. coli mchF, hemL, iroN, iss
3512 AUT dog vaginal swab E. coli lpfA, hemL, intl1, iss, fimH, iucD
2srb SRB dog urin E. coli lpfA, cma, hemL, intl1, iroN, iss, fimH, iucD
1srb SRB dog urin E. coli iha, prfB, astA, sat, senB, hemL, fimH, papC
ESBL1 SRB cat vaginal swab E. coli iucD
ESBL41 SRB dog vaginal swab E. coli fimH, iucD
3. Discussion
Among Austrian E. coli isolates, clones belonging to B2 (phylotype)-O25b:H4 (serotype)-ST131
(sequence type) -CH40-30 (clonotype) -CTX-M-15 and FQR isolated from a canine prostate specimen
and E. coli F-ONT(non-typeable):H6-ST648-CH4-27-CTX-M-15 (and FQR resistant) isolated from a
vaginal swab of a dog were the most significant. The same applies to NDM-1 positive Enterobacter cloacae
from Serbia. E. coli O25b:H4-ST131 (CH40-30 [CTX-M-15]) is widely recognized as one of the most
important pandemic pathogens. This clone has been shown to cause various infections in humans
and animals ranging from asymptomatic bacteriuria to complicated UGIs, septicemia, meningitis,
and pneumonia. In several publications E. coli ST131 has been unanimously classified as ExPEC and/or
UPEC [1,2,4,7,8,11,12,14,15,17,35,38–40]. According to origin and site of infection, E. coli ST131 strains
were additionally categorized as FUPEC, NEMEC, APEC or SEPEC. It is believed that the global
dissemination of E. coli ST131 as well as E. coli ST648 has contributed to the worldwide emergence of
CTX-M-15 producing E. coli [14,41]. Anyway, CTX-M-15 is a mostly plasmid-transferable gene and not
all ST131 E. coli isolates harbor it. Thus, E. coli ST131 may be susceptible to cephalosporins [42]. ST131 is
mostly (but not necessarily) associated with fluoroquinolone resistance [35,43]. So far, CTX-M-15
harboring and fluoroquinolone-resistant E. coli B2-O25b:H4-ST131 has been described as the cause of
UGI in dogs in Portugal, the Netherlands, Switzerland, the United Kingdom and France [24,33]. It has
also been isolated from dogs and cats in the USA, from dogs, cats and horses in Denmark, Germany
and Spain and from dogs in China [35,44]. E. coli B2-O25b:H4-ST131-CTX-M-27 variant has been
isolated from urine specimen of dogs and cats in Japan [31]. Non CTX-M-15, fluoroquinolone-resistant
E. coli B2-O25b:H4-ST131 has also been detected in the urinary tract of dogs and cats in the USA and its
transmission from companion animals to humans has been suspected suggesting dogs and cats as
possible reservoir of this clone [14]. However, E. coli ST131 has never been reported to be isolated from
the prostate of a dog, as was the case in our study. Zoonotic transmission of E. coli ST131 is still the
subject of scientific debates. Transmission of E. coli ST131 from poultry to humans and rats has been
observed and transfer of E. coli ST131 via meat products, particularly from chicken meat to humans
causing UGI has been proven [2,13,17]. In Austria, this pandemic clone has only been isolated from
wildlife so far [45].
Another clone, E. coli F (D)-ST648 (CTX-M-15) which also has readily been classified as ExPEC
or/and UPEC was recognized as the zoonotic pandemic agent of various types of infections most
common in humans but also in livestock and companion animals [40]. It has been detected in pigs,
calves and other livestock in Germany and the Netherlands, dogs and cats in the USA, Germany
and Italy as well as in wild birds in Mongolia and Germany [34]. It was first isolated as a cause of
cystitis in a cat in 2013 in Switzerland [15], later it has been detected in urine samples of dogs with
UGI, also in Switzerland [33]. It was a frequently isolated clone (D-ST648 [CMY, TEM]) from intestinal
samples originating from stray dogs reported in a study from South Korea [23]. Another significant
finding in this study is, to our knowledge the first isolation of a CTX-M-15 and NDM-1, together with
OXA 1, TEM producing Enterobacter cloacae ST114 from a vaginal swab of a dog from Serbia (strain
ESBL40). Carbapenems-resistance in bacteria of animal origin is a subject of great concern due to their
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importance in therapy of life-threatening infections in human and in veterinary medicine [26,43,46].
Although several publications state that the risk of carbapenem resistance in animals is low due to the
limited use of this class in veterinary medicine [26,43,46], this is the second report on the detection of
carbapenemases carrying bacteria associated with canine UGI from Serbia [36] and blaNDM, blaVIM,
blaIMP, blaOXA and blaKPC carbapenemases have been detected worldwide in companion animals.
Unlike carbapenemases, CTX-M-15 is highly prevalent in Enterobacter cloacae and CTX-M-15-producing
ST114 Enterobacter cloacae has been recently reported as a high-risk clone for public health which was
predominant in cats, dogs and horses [47,48].
Of the other ST found in our study, E. coli ST744 was represented by three isolates (B1-ONT:H9-
ST744-CH11-54 [TEM]; C-ONT:H9-ST744-CH11-0 [CTX-M-1, TEM]; C-ONT:H9-ST744-CH4-31 [CTX-M-1,
TEM]). This ST has previously been isolated from urine samples of dogs (carrying CTX-M-1, CTX-M-15,
CTX-M-14) [33] and E. coli ST744-CTX-M-1 was also reported in livestock [43].
In our study, one AmpC/ESBL E. coli C-O9:H9-ST1287-CH11-54 (TEM, CMY) was detected in a
vaginal swab of a dog. Fluoroquinolone resistant, non-AmpC, non-ESBL E. coli ST1287 categorized as
APEC has been reported in a parrot pet from Brazil [49] and in a blood sample from a patient with
septicemia as well as in the feces of a healthy individual [21,50]. This ST seems to be rare and, to our
knowledge, AmpC/ESBL/FQR E. coli ST1287 has been isolated from a dog for the first time.
E. coli B1-ST469 and B1-ST1463, which have also been found in our study, have rarely been
reported, mostly in humans and turkey [22]. To the best of our knowledge, these two STs have not
been isolated from cases of UGI in companion animals, so far.
One E. coli isolated from the vagina of a dog has been typed as B1-ONT:H7-ST1642-CH11-54
(TEM). The same ST (B1-O8:H7-ST1642) harboring CTX-M-55 has been isolated from a urine specimen
of a cat in Japan [31], the CTX-M-14 harboring variant has been detected in human blood samples [40],
the CTX-M-15 variant has been found in feces of healthy lambs in Brazil [30] and the E. coli B1-ST1642
harboring blaTEM and blaCMY has been detected in an intestinal specimen from a stray dog in South
Korea [23].
In CTX-M harboring isolates, blaCTX-M-1 was more common which is also inconsistent with
findings in other studies mostly reporting CTX-M-15 being predominant among ESBL producing
enterobacteria isolated from humans and animals [24]. In addition, CTX-M-14 and CTX-M-55
harboring Enterobacterales have been increasingly reported in companion animals [23,24], which were
not detected in our investigation. The least prevalent CTX-M variant was blaCTX-M-9, detected in one
AmpC/ESBL/FQR E. coli from Austria (ID 4) (Clade II-CH10-58 [CTX-M-9, TEM]). In one large study
among companion animals in China, out of 107 CTX-M producing E. coli, only one was CTX-M-9 [51].
In another study from UK, out of 876 investigated and 164 cephalosporin-resistant E. coli originating
from companion animals, neither one harbored CTX-M-9 [24].
Based on the published surveys [19,26–28], the use of critically important antimicrobials (amongst
them 3rd and 4th generation cephalosporins and fluoroquinolones) is cited as being frequently
prescribed for dogs and cats in a number of countries including Belgium, Spain, France, the United
Kingdom and Germany. Carbapenems are mostly prescribed in complicated cases (MDR infections)
based on results of susceptibility testing and treatment durations are longer than typically recommended
in human medicine [26].
In our study, MDR (ESBL/FQR) E. coli ST131 (555) and Klebsiella pneumoniae (3824) have been
isolated from two canine prostate samples. Not all antibiotics are capable of penetrating the prostate
tissue, so the therapy choice is initially limited to enrofloxacin, trimethoprim and fosfomycin [18].
Both prostate isolates from our study were susceptible only to fosfomycin which has not been licensed
for the use in companion animals, neither in Serbia, nor in Austria. Therefore, this antibiotic is not
included in routine susceptibility testing, though out of label use would be feasible. Besides, CLSI
does not provide interpretative categories for fosfomycin in its document [29] and human-related
interpretative categories may be used, although interpretation should then be performed with caution.
The finding of MDR bacteria in the canine prostate (including human-related clones such as E. coli
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ST131) is becoming a reality and one should expect more such cases in the future. Besides, out of
36 MDR strains included in this study, 35 were susceptible to fosfomycin. The only fosfomycin resistant
strain was a carbapenem resistant Enterobacter cloacae ST114 isolated from the vagina of a Serbian
dog. Since fosfomycin is a critically important human-related antibiotic according to WHO [52],
the emergence of bacterial strains susceptible only to fosfomycin in companion animals may lead to an
undesired, more frequent use of this antibiotic in veterinary medicine in the future.
Ten E. coli and the Citrobacter portucalensis isolate (9 originating from urine samples) from our
study exhibited an ESBL/AmpC/FQR resistance phenotype and all were susceptible to nitrofurantoin
and fosfomycin. Nitrofurantoin has also been listed in the ISCAID for the treatment of MDR related
UGIs in companion animals. Interpretative categories for nitrofurantoin are presented in the CLSI
VET01, Ed4E document, though nitrofurantoin has not been licensed for use in companion animals,
neither in Austria nor in Serbia.
Although it has been proven that ExPEC/UPEC clones that share the same antibiotic resistance
patterns may cause UGIs in humans as well as in animals, recommendations for the treatment of
UGIs in humans differ significantly from guidelines related to animals. The Infectious Diseases
Society of America (IDSA) in collaboration with the European Society for Microbiology and
Infectious Diseases (ESCMID) removed beta-lactams and fluoroquinolones from the list of first-line
antibiotics for the treatment of uncomplicated UGIs in adult humans [53]. Instead, nitrofurantoin,
trimethoprim-sulfamethoxazole and fosfomycin are recommended. Amoxicillin and ampicillin have
been removed because of their relatively poor efficacy and the high prevalence of antimicrobial
resistance to these agents worldwide [53].
There are no defined criteria for strict categorization of E. coli strain as ExPEC or UPEC or any
other subcategory (APEC, NEMEC, SEPEC), because all these subcategories mostly share the same
virulence genes [1,4,7–9,13,17,38,39,54–56]. Some authors assume that the presence of at least two of
the following genetic determinants indicates categorization of an isolate as ExPEC/UPEC: papA and/or
papC (P fimbriae structural subunit and assembly), sfa/focDE (S and F1C fimbriae), afa/draBC (Dr
binding adhesins), iutA (aerobactin system) and kpsM II (group 2 capsule) [1]. This minimal predictive
set of ExPEC virulence genes has not been thoroughly validated and thus is considered incomplete
as strains meeting this definition do not always cause disease. Accordingly, drawbacks of such a
scheme were shown in a study [57] in which E. coli ST648 has been categorized as pandemic ExPEC
but results demonstrated that out of 47 ST648 isolates only 17 were assignable to ExPEC based on
the aforementioned scheme. Thus, we did not use this scheme in our study. However, since we
considered iucD and iutA to have the same function [40] encoding aerobactin ferric receptors, 3 of
our investigated isolates that were shown to harbor papC/iucD could potentially be classified as
ExPEC/UPEC. Those were isolate 555 (B2-O25b:H4-ST131-CH40-30 [CTX-M-15, OXA1]) and further
two isolates which belonged to the cam fumC cluster 2058 (O25:H4CH40-22 [CTX-M-1, TEM]) and
3056 (O25:H4CH40-30 [CTX-M-1, OXA-1]) probably sharing the same ST.
Another approach is to associate virulence factor(s) (VF(s)) with ST, CH types, phylogroups,
antibiotic resistance and thus to establish pathogenic and zoonotic potential of the suspected ExPECs.
Therefore, we included VFs mostly associated with ExPEC or UPEC [17] amongst them papC, fimH,
iucD, sat, cnf 1, iss, iha, ast, nfa, iroN, tsh and hly. Based on this expanded list of VFs our 18 isolates
investigated can be assigned to ExPEC/UPEC (containing 3 or more VFs from the expanded VF list).
The fimH gene was found in 61% (n = 20 Austrian and n = 2 Serbian) isolates. It encodes
FimH adhesins/type 1 fimbriae, which are essential virulence factors for uropathogenic E. coli and
their successful colonization of the urinary bladder epithelium [58] but are also referred as a major
virulence factor of E. coli belonging to the ExPEC category [5,6,58]. Anyway, this type of adhesin is not
only typical for uropathogenic but also for intestinal as well as enterohaemorrhagic (EHEC) isolates.
Reports show that fimH is equally represented in E. coli isolated from both humans and animals [59].
The gene iucD encodes for an enzyme included in the aerobactin biosynthesis pathway [60].
The aerobactin siderophore system is an important virulence factor and it is absent in avirulent
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E. coli strains, thus, finding iucD in 55% (n = 15 Austrian, n = 5 Serbian) may serve as evidence for
pathogenicity of the isolates [60]. The secreted autotransporter toxin SAT is a virulence factor of UPEC
and/or diffusely adhering E. coli (DAEC) both associated with pyelonephritis and urosepsis [61]. Sat is
reported to be predominant in E. coli of human origin [57]. In our study, it was found in 3 isolates,
two from Austria (555: B2-O25b:H4-ST131-CH40-30; 3056: O25:H4-CH40-30) and one from Serbia
(1srb: C-CH11-0 [TEM, OXA-2]). The latter also harbored the ast gene encoding heat-stable enterotoxin
1 which is mostly found in ETEC, thus isolate 1srb probably belonged to diarrheal E. coli.
P fimbriae (pap) are the second common virulence factor of UPEC, which plays an important role
in the pathogenesis of ascending UGIs and pyelonephritis in humans [61], it was found in 13.8% (n = 5)
isolates in our study.
Gene tsh encoding temperature-sensitive haemagglutinin was found in two Austrian (3441:
C-ONT:H9-ST744; 3448: C-ST744) and one Serbian strain (MDR56: A-O128:H26). It is predominant in
E. coli isolated from animals [57] and mostly present in APECs as previously reported with a prevalence
of more than 50% in APEC, 4.5% in UPEC and 11.5% in NMEC isolates tested [5]. Strain MDR56 C-STNT
probably was of intestinal origin. This is supported by the finding that it belongs to phylogroup A to
which commensal E. coli from the gastrointestinal tract mostly belong [38]. Besides, MDR56 was typed
as O128 (H26) which is a serotype often reported as shiga toxin-producing E. coli (STEC) mostly found
in sheep and humans [59]; however, MDR56 was shown to be negative for stx.
The increased serum survival gene iss has been reported in E. coli isolated from humans and
animals [57] and in approximately 60% of UPEC and NMEC strains. It has also been associated with
APEC strains [60]. In our study it was found in 55% (n = 20) of isolates.
4. Materials and Methods
During the study period between October 2010 and March 2015, 2398 samples from Austria as
well as between January 2012 and March 2015, 144 samples from Serbia taken from the canine and
feline urogenital tract were considered in the present study. If the microbiological examination
yielded bacterial growth, isolates were identified to the species level by matrix-assisted laser
desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (Bruker Daltonik, Heidelberg,
Germany). Antimicrobial susceptibility testing was performed by agar disk-diffusion according to
standards of the Clinical and Laboratory Standards Institute (CLSI) [62]. Escherichia coli ATCC® 25922
served as quality control strain. The following antimicrobials were used—ampicillin, cefotaxime,
ceftazidime, cefepime, aztreonam, meropenem, gentamicin, amikacin, tobramycin, ciprofloxacin,
trimethoprim-sulfamethoxazole, tetracycline fosfomycin, nitrofurantoin and chloramphenicol (Becton
Dickinson, Heidelberg, Germany). In addition, isolates were checked for extended-spectrum
β-lactamase (ESBL) production by ESBL-test via agar disk diffusion combination disk tests using
cefotaxime and ceftazidime with and without clavulanic acid [62]. Furthermore, cefoxitin (30 µg)
was added to this test, to detect AmpC phenotypes. Isolates belonging to Enterobacterales and
were broad-spectrum cephalosporin-resistant and/or fluoroquinolone-resistant were included in the
present study.
All isolates were obtained from samples during routine bacteriological diagnostics at the Institute
of Microbiology, University of Veterinary Medicine, Vienna, Austria as well as the Department for
Microbiology, Faculty of Veterinary Medicine University of Belgrade, Serbia. All these clinical samples
were received from third parties and therefore not subject to reporting obligations of the Ethics and
Animal Welfare Commission of the University of Veterinary Medicine in Vienna and not subjected
to Ethics Commission for the experimental animals welfare protection of the Faculty of Veterinary
Medicine in Belgrade. All isolates were stored at −80 ◦C until further examination.
The serogenotyping and the detection of resistance genes and major virulence genes of E. coli
isolates was performed using the miniaturized microarray-based E. coli PanType AS-2 kit (Alere, Jena,
Germany). The same assay was used to detect resistant determinants in non-E. coli Enterobacterales.
Resistance genes in one carbapenem-resistant Enterobacter cloacae-complex isolate were analyzed by
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CarbDetect-AS-2 Kit microarray (Alere, Jena, Germany) [63,64]. PCRs were performed to detect tet(A)
and tet(B) in carbapenem resistant Enterobacter cloacae as well as to amplify blaNDM and blaCTX which were
then sequenced [65,66]. Sequences were aligned with BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and
compared with reference sequences available in GenBank and the National Center for Biotechnology
Information (NCBI) database (http://www.ncbi.nlm.nih.gov/pathogens/beta-lactamase-data-resources/).
The quinolone resistance-determining regions (QRDR) of gyrA and parC in ciprofloxacin-resistant isolates
were amplified by PCR and sequenced [67]. E. coli isolates displaying the AmpC phenotype were also
analyzed for mutations in the chromosomal ampC promoter/attenuator region as described previously [68].
Allele-specific PCR was performed to identify the O25 clone of selected E. coli isolates [69]. The E. coli
isolate was assigned to a phylogroup using the quadruplex assignment method [70]. Clonal relatedness of
E. coli isolates was assessed by two-locus sequence typing of combined data of fumC and fimH sequences
as described by Weissman et al. [71]. Allele and CF clonotype numbers were used for goeBURST
analysis using PHYLOViZ [72]. Selected E. coli isolates were further subjected to multilocus sequence
typing (MLST) [73]. Allelic profiles and sequence types (ST) were determined by querying the E. coli
MLST website (http://enterobase.warwick.ac.uk/species/ecoli/allele_st_search). The carbapenem-resistant
Enterobacter cloacae isolate was characterized by MLST according to the protocol recommended by
Miyoshi-Akiyama et al. [74] and ST was determined using Enterobacter cloacae MLST database (https:
//pubmlst.org/ecloacae/).
5. Conclusions
The study discovered E. coli B2-O25b:H4-ST131-CH40-30-CTX-M-15 and FQR in a prostate
specimen from a dog and E. coli F (D)-ONT:H6-ST648-CH4-27-CTX-M-15 and FQR in a canine vaginal
sample, which are important pandemic pathogens that have been shown to cause various infections in
humans and animals. Furthermore, carbapenem-resistant Enterobacter cloacae ST114 harboring blaNDM,
blaCTX-M-15, blaOXA-1 and blaTEM was detected in a canine vaginal swab from Serbia, which is considered
to be the first report of NDM-1 harboring Enterobacter cloacae isolated from a dog. The findings in
this study suggest a possible reverse zoonotic transmission of ExPEC/UPEC—companion animals
may be infected by human-related clones because of their close co-existence and then may become an
important source of those clones for the human population.
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